Voriconazole (ZP-059)

Small molecule

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Allergic Bronchopulmonary Aspergillosis

Competitive landscape

This drug's own stage for Allergic Bronchopulmonary Aspergillosis: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Voriconazole (ZP-059): this drugPhase 1Small moleculefungal CYP51 / lanosterol 14-alpha-demethylaseWeak signalFeatured results are safety only in this race
Itraconazole (PUR1900)Phase 2Small moleculefungal CYP51 (lanosterol 14α-demethylase)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.